La chaîne d'options affiche les données clés des options sur actions de Repare Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Repare Therapeutics..

Repare Therapeutics (NASDAQ:RPTX) Stock, Chaîne d'Options

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.

Repare Therapeutics Inc

GORV

Lazydays Holdings Agreed To Exchange All Outstanding Convertible Preferred Stock For Common Stock At $1.03 Per Share

<a href="https://www.clinicaltrials.gov/study/NCT04994483?cond=Alzheimer%20Disease&amp;term=simufilam&amp;rank=3" title="https://www.clinicaltrials.gov/study/NCT04994483?cond=Alzheimer%20Disease&amp;term=simufilam&amp;rank=3">https://www.clinicaltrials.gov/study/NCT04994483?cond=Alzheimer%20Disease&amp;term=simufilam&amp;rank=3</a>

Biotech

Trading Ideas

General

SAVA

Cassava Sciences' Simufilam 100 Mg For Mild-To-Moderate Alzheimer's Disease (RETHINK-ALZ) Posted On ClinicalTrials Website On November 15, 2024

UBS analyst Brian Reynolds maintains MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) with a Buy and raises the price target from $51 to $55.

News

Price Target

Analyst Ratings

MPLX

UBS Maintains Buy on MPLX, Raises Price Target to $55

Stifel analyst Drew Crum maintains OneWater Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) with a Buy and lowers the price target from $34 to $31.

ONEW

Stifel Maintains Buy on OneWater Marine, Lowers Price Target to $31

UBS analyst Shneur Gershuni maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Buy and raises the price target from $232 to $265.

UBS Maintains Buy on Cheniere Energy, Raises Price Target to $265

Last month, U.S. District Judge Jesse Furman of the U.S. District Court for the Southern District of New York dismissed a $6.4 billion lawsuit against issuer Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
The plaintiff, UMB Bank, had not been properly <a href="https://www.milbank.com/a/web/r333FErFizuVNYcVKYmE5F/law360-bristol-myers-win-offers-lessons-for-debt-security-holders.pdf" target="_blank" rel="noreferrer noopener">appointed</a> as the trustee for the securities and therefore lacked standing to sue on behalf of the directing holders.
The issue undermined the lawsuit, filed 17 months after Bristol Myers acquired Celgene for $80.3 billion in 2019.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock" rel="noreferrer noopener">Bristol-Myers Squibb&#8217;s $14 Billion Potential &#8211; Analyst Upgrades Stock</a>
UMB Bank NA filed suit against Bristol-Myers in 2021. The firm alleges that the company intentionally slow-rolled the approval process for a cancer drug to dodge paying $6.4 billion owed to former Celgene shareholders under a contingent value rights agreement.
On Thursday, Bristol Myers Squibb was again hit with a $6.7 billion lawsuit. The company allegedly delayed federal approval for three drugs to avoid paying former Celgene shareholders.
The case, filed by UMB Bank, claims the delay cost &#8220;contingent value rights&#8221; (CVR) holders an extra $9 per share in cash. The drugs involved include the cancer treatment Breyanzi.
In the third quarter of 2024, Breyanzi generated sales of $224 million, up from <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">$92 million a year ago</a>.
Per Reuters, UMB resolved the appointment issue. The bank is now confirmed as trustee, allowing it to proceed with the lawsuit. The estimated liability has increased from $6.4 billion to $6.7 billion.
Price Action: BMY stock is down 0.19% at $58.39 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42008174/fda-to-revisit-regeneron-sanofis-dupixent-for-rare-skin-disease" target="_blank" rel="noreferrer noopener">FDA To Revisit Regeneron/Sanofi&#8217;s Dupixent For Rare Skin Disease</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Legal

Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue

Camping World To Acquire Seven Dealerships From Lazydays, Adding Nearly $200M In TTM Revenue; Transaction Valued Around Book Value With $10M-$20M Net Cash Outlay And Conversion To 9.7M Lazydays Shares

Stifel analyst Jeffrey Stantial maintains Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) with a Buy and raises the price target from $13 to $14.

GAMB

Stifel Maintains Buy on Gambling.com Gr, Raises Price Target to $14

RBC Capital analyst Arthur Nagorny maintains SNC-Lavalin Gr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATRL#TSX">ATRL</a>) with a Outperform and raises the price target from C$70 to C$84.

TSX:ATRL

RBC Capital Maintains Outperform on SNC-Lavalin Gr, Raises Price Target to C$84

UBS analyst Manav Gupta maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Buy and raises the price target from $30 to $33.

UBS Maintains Buy on Kinder Morgan, Raises Price Target to $33

Investors with significant funds have taken a bearish position in Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in MPWR usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 10 options transactions for Monolithic Power Systems. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 0% being bullish and 60% bearish. Of all the options we discovered, 9 are puts, valued at $553,035, and there was a single call, worth $46,580.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $470.0 and $800.0 for Monolithic Power Systems, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Monolithic Power Systems's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Monolithic Power Systems's significant trades, within a strike price range of $470.0 to $800.0, over the past month.
<h3>Monolithic Power Systems Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731685581_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$218.3</td>
<td>$209.1</td>
<td>$213.02</td>
<td>$800.00</td>
<td>$127.8K</td>
<td align="right">103</td>
<td align="right">15</td>
</tr>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$166.0</td>
<td>$156.0</td>
<td>$163.67</td>
<td>$750.00</td>
<td>$81.8K</td>
<td align="right">14</td>
<td align="right">5</td>
</tr>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$117.5</td>
<td>$109.0</td>
<td>$117.5</td>
<td>$700.00</td>
<td>$58.7K</td>
<td align="right">25</td>
<td align="right">10</td>
</tr>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$116.0</td>
<td>$111.1</td>
<td>$116.0</td>
<td>$700.00</td>
<td>$58.0K</td>
<td align="right">25</td>
<td align="right">15</td>
</tr>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$117.5</td>
<td>$107.5</td>
<td>$115.0</td>
<td>$700.00</td>
<td>$57.5K</td>
<td align="right">25</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Monolithic Power Systems</h3>
Monolithic Power Systems is an analog and mixed-signal chipmaker, specializing in power management solutions. The firm's mission is to reduce total energy consumption in end systems, and it serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.
<h3>Current Position of Monolithic Power Systems</h3>
<ul>
<li>Currently trading with a volume of 386,024, the MPWR's price is up by 0.56%, now at $580.0. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>What Analysts Are Saying About Monolithic Power Systems</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $887.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Loop Capital lowers its rating to Hold with a new price target of $660. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Monolithic Power Systems, targeting a price of $950. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $950. 
&#x2A; An analyst from Oppenheimer has revised its rating downward to Outperform, adjusting the price target to $900. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Monolithic Power Systems with a target price of $975. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Monolithic Power Systems, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

MPWR

Decoding Monolithic Power Systems's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $412,586, and 2 are calls, for a total amount of $75,090.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $82.5 to $120.0 for Novo Nordisk over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $82.5 to $120.0 over the preceding 30 days.
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731685576_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$92.50</td>
<td>$161.8K</td>
<td>653</td>
<td>693</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.66</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$90.00</td>
<td>$81.0K</td>
<td>9.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$5.05</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$105.00</td>
<td>$45.5K</td>
<td>740</td>
<td>157</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$19.15</td>
<td>$19.05</td>
<td>$19.05</td>
<td>$120.00</td>
<td>$43.8K</td>
<td>3.3K</td>
<td>42</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$92.50</td>
<td>$39.0K</td>
<td>653</td>
<td>162</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,812,025, with NVO's price down by -3.84%, positioned at $101.28.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About Novo Nordisk</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $158.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $156. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On Novo Nordisk

Investors with a lot of money to spend have taken a bullish stance on AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ASTS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for AST SpaceMobile.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 31%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $238,650, and 10 are calls, for a total amount of $2,473,300.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $50.0 for AST SpaceMobile during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AST SpaceMobile's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AST SpaceMobile's substantial trades, within a strike price spectrum from $15.0 to $50.0 over the preceding 30 days.
<h3>AST SpaceMobile Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731685571_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.0</td>
<td>$8.1</td>
<td>$8.8</td>
<td>$35.00</td>
<td>$1.7M</td>
<td>5.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.0</td>
<td>$6.3</td>
<td>$6.8</td>
<td>$50.00</td>
<td>$272.0K</td>
<td>4.7K</td>
<td>455</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$23.00</td>
<td>$80.0K</td>
<td>8</td>
<td>200</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.65</td>
<td>$2.45</td>
<td>$2.51</td>
<td>$25.00</td>
<td>$75.2K</td>
<td>2.0K</td>
<td>428</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$35.00</td>
<td>$72.6K</td>
<td>2.5K</td>
<td>935</td>
</tr>
</tbody>
</table>

<h3>About AST SpaceMobile</h3>
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers and finally bringing broadband to the billions who remain unconnected. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
<h3>Where Is AST SpaceMobile Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 7,710,911, with ASTS's price down by -13.02%, positioned at $23.31.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 136 days.</li>
</ul>
<h3>What Analysts Are Saying About AST SpaceMobile</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $31.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on AST SpaceMobile with a target price of $31. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AST SpaceMobile, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ASTS

Market Whales and Their Recent Bets on ASTS Options

<a href="https://suspilne.media/881015-zelenskij-z-administracieu-trampa-vijna-zaversitsa-svidse/" title="https://suspilne.media/881015-zelenskij-z-administracieu-trampa-vijna-zaversitsa-svidse/">https://suspilne.media/881015-zelenskij-z-administracieu-trampa-vijna-zaversitsa-svidse/</a>

Macro Notification

Zelenskiy Tells Ukraine's Suspilne Broadcaster: War Will 'End Sooner' Under Trump Administration

Stifel analyst Adam Borg maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $320 to $340.

ADSK

Stifel Maintains Buy on Autodesk, Raises Price Target to $340

<a href="https://www.benzinga.com/news/24/11/41884428/warren-buffetts-166-billion-warning-to-wall-street-has-hit-a-fever-pitch-and-the-financial-world-cant-afford-to-ignore-it">Warren Buffett's</a> investment strategy is a case study in bold and safe play. Nearly $99 billion is pegged on two iconic names: Apple and Coca-Cola. Through Berkshire Hathaway, Buffett has channeled a whopping half of his equity holdings into Apple alone and he's held tight to his Coca-Cola shares since the late 1980s.&nbsp;
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</a></li>
</ul>
His strategy here is simple but powerful – backing companies with brand strength and consistent financials. Apple's stock, for instance, surged 31% this year and many see this as Buffett's savviest move yet. Some say it's his "crown jewel," lauding his foresight in spotting a tech company that's proven as resilient as it is profitable.
But as with any big bet, Buffett's heavy reliance on Apple has sparked some chatter. Skeptics say putting so many eggs in one tech basket could be risky. With tech stocks, there's always the threat of shifting consumer trends, not to mention the occasional market shake-up.&nbsp;
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
And while Apple has shown impressive gains this year, the latest numbers hint at a slight cooling. In the last fiscal year, Apple's total revenue dipped by 0.8% – a small shift but enough to raise eyebrows. Still, Morgan Stanley analyst Erik Woodring believes Apple has room to climb, setting a price target of $273, which would mark a 20% rise from current levels.
Apple's pivot toward services is holding it steady. Though iPhone sales may ebb and flow, Apple's revenues from the App Store, streaming and cloud services have grown by 23% over the past few years.&nbsp;
Services have also helped Apple boost its profit margins, going from 43.3% in 2022 to 46.2% in 2024, catching Wall Street's attention. These margins and the cash flow from services make Apple's high share prices easier to swallow, especially as it could mean bigger dividends for shareholders.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Then there's <a href="https://www.benzinga.com/personal-finance/24/07/40046044/grant-cardone-says-buffett-made-508-million-as-an-investor-in-coca-cola-last-year-the-ceo-made-5">Coca-Cola</a>, which stands out as Buffett's textbook choice. It's familiar, steady and beloved worldwide. His initial investment in Coca-Cola in the late ‘80s has since grown to a $27.67 billion stake and despite recent bumps – like a 12% drop from September's peak – investors still see value here.&nbsp;
Morgan Stanley's Dara Mohsenian predicts Coca-Cola could climb to $76 a share, marking a potential 19% increase. Investors love Coca-Cola for its dependable growth and steady dividend payouts. Coca-Cola just raised its dividend for the 62nd consecutive year, offering a 3% yield – a rarity in today's market.&nbsp;
Unlike the roller-coaster nature of tech, Coca-Cola's simpler, time-tested business model gives it a stability that's hard to beat. The company's revenue ticked up, with a 5.0% rise in the first nine months of 2024 alone and management projects 10% organic sales growth for the year – proof of the brand's staying power.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</a></li>
</ul>

Startups

$99 Billion Bet: Warren Buffett Invests Heavily In 2 Stocks Expected To Jump 19% And 20%, Wall Street Analysts Predict

Kulicke and Soffa Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>) shares were rising in early trading on Friday, after <a href="https://www.benzinga.com/quote/KLIC">shedding more than 5% this week</a>.
While reporting earnings, the company announced an order for fluxless TCB from "the world&#8217;s leading foundry," which could be chipmaker Taiwan Semiconductor Mfg. Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), according to Needham.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60ed6112b473c600014bf1c9/charles-shi">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60ed6112b473c600014bf1c9/charles-shi">Charles Shi</a> upgraded the rating for Kulicke and Soffa Industries from Hold to Buy, while establishing a price target of $55.
The Kulicke and Soffa Industries Thesis: Given in order, the company expects TCB revenues to grow by 40%-50% year-on-year in 2025, Shi said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Kulicke and Soffa Industries is expected to generate TCB revenues of around $55 million in 2024, which could now reach as much as $80 million next year, "beating our $70MM estimate by about $10MM," he added.
Rival ASMPT is likely to have failed the TCB qualification at Taiwan Semiconductor and its management said during the third-quarter earnings call that TCB evaluation at the leading foundry "may take another year," the analyst stated.
"To us, the fact that KLIC is already qualified and shipping while ASMPT still has not closed the evaluation means that KLIC has won," he further wrote.
KLIC Price Action: Shares of Kulicke and Soffa Industries rose by 2% to $46.52 at the time of publication on Friday.
Read More: • <a href="https://www.benzinga.com/news/global/24/11/41972365/tsmcs-65b-investment-in-us-will-help-avoid-trade-imbalance-says-taiwan-central-bank-governor-as-trump-returns-to-white-house">TSMC&#8217;s $65B Investment In U.S. Will Help Avoid Trade Imbalance, Says Taiwan Central Bank Governor As Trump Returns To White House</a>
Photo: Screenshot from Kulicke and Soffa video

Analyst Color

Earnings Beats

Long Ideas

Upgrades

Movers

Tech

KLIC

Kulicke And Soffa Industries Likely To Win Order From Leading Semiconductor Company, Says Bullish Analyst

Macro Economic Events

Market Summary

Economics

AMAT

MRNA

Benzinga Market Summary: Vaccine Stocks Fall On Trump's Planned RFK Jr. Nomination To HHS, Applied Materials Stock Falls Following Earnings, Domino's Rises On Berkshire Hathaway Stake

RBC Capital analyst Jimmy Shan maintains Automotive Props REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/APR#TSX">APR</a>) with a Sector Perform and raises the price target from C$12.5 to C$13.

TSX:APR

TSX:APR/UN

RBC Capital Maintains Sector Perform on Automotive Props REIT, Raises Price Target to C$13

UBS analyst Cody Ross maintains Ingredion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) with a Buy and raises the price target from $165 to $173.

INGR

UBS Maintains Buy on Ingredion, Raises Price Target to $173

Repare Therapeutics (RPTX) presented updated data highlighting the benefits of its individualized schedule for the management of anemia in the Phas...

Repare Therapeutics presents data from Phase 1 MYTHIC clinical trial

TD Cowen analyst Marc Frahm maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today. The company's shares closed yesterday at...

TD Cowen Sticks to Its Buy Rating for Repare Therapeutics (RPTX)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics (RPTX – Research Report), with a price...

Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes

Reports Q3 cash, cash equivalents and marketable securities as of September 30 were $179.4M. The Company believes that its cash, cash equivalents, ...

Repare Therapeutics reports Q3 EPS (81c), consensus (83c)

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Repare Therapeutics (RPTX – Research Report), with a price ...

Repare Therapeutics: Strategic Clinical Advancements and Promising Data Drive 'Buy' Rating

Repare Therapeutics Inc ( ($RPTX) ) has released its Q3 earnings. Here is a breakdown of the information Repare Therapeutics Inc presented to its i...

Repare Therapeutics Reports Q3 2024 Progress and Outlook

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Repare Therapeutics (RPTX – Research Report), retaining the price target of $10....

Repare Therapeutics: Strong Financial Health and Promising Data Catalysts Justify Buy Rating with $10 Price Target

TD Cowen analyst Marc Frahm has maintained their bullish stance on RPTX stock, giving a Buy rating on November 8. Marc Frahm's rating is based on a...

Repare Therapeutics: Promising Oncology Advances and Financial Stability Support Buy Rating

Repare Therapeutics (RPTX) announced a cooperative research and development agreement, or CRADA, has been executed to advance the development of ca...

Repare Therapeutics announces CRADA to advance camonsertib development

Repare Therapeutics collaborates with U.S. National Cancer Institute

RPTX

Press Releases

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Comments

Repare Therapeutics

Repare Therapeutics (RPTX) Options

Repare Therapeutics (NASDAQ:RPTX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL